Infliximab vs adalimumab in Crohn’s disease

The first Australian audit directly comparing infliximab and adalimumab as induction and maintenance therapy in Crohn’s disease has concluded that the TNF inhibitors lead to similar clinical and biochemical outcomes, but infliximab may have the edge in controlling fistulising disease. Dr Poornima Varma and colleagues in Melbourne audited 81 patients treated at the Alfred Hospital, ...

Already a member?

Login to keep reading.

© 2021 the limbic